Avalyn Raises $175 Million In Oversubscribed Series C Financing To Advance Inhaled Pulmonary Fibrosis Programs Into Later Stage Clinical Studies
Amount Raised
$175 Million
Round Type
Series C
SeattleBiotechnologyHealthcareHealth CareDescription
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, announced the closing of an oversubscribed $175 million Series C financing. Avalyn plans to use the funds to continue development of its portfolio of inhalation therapies for interstitial lung disease that improve upon currently approved medications, and advance lead clinical assets, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), into mid-stage clinical trials.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Avalyn that raised within 45 days of this round, from Fundz verified event records.
- ReAlta Life Sciences raised $30M on November 7, 2023.
- Greenbrook TMS raised $2M (Seed) on November 2, 2023.
- Yarrow Bioscience raised $88M on November 1, 2023.
- Gyre Therapeutics raised $5M on October 30, 2023.
- Pharmazz raised $450K (Seed) on October 24, 2023.
- Lipella Pharmaceuticals raised $3.1M (Seed) on October 23, 2023.
Who to call at Avalyn, and when
A new round usually means Avalyn is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Avalyn raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Avalyn, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Avalyn. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Avalyn raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Avalyn raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.